

**BJMHR**British Journal of Medical and Health Research  
Journal home page: [www.bjmhr.com](http://www.bjmhr.com)

## **COVID-19, an emerging coronavirus infection: Advances and prospects in designing convalescent sera, immunotherapeutics and therapeutics**

**Suman Saurabh Gupta<sup>1\*</sup>, Monika Upadhyay<sup>1</sup>, V.D Dafle<sup>2</sup>***1.Department of Pathology, Postgraduate Resident , Dy Patil Medical College , Kolhapur, Maharashtra**2.Department of Pathology, Assistant Professor, D Y Patil Medical College , KOLHAPUR, Maharashtra*

### **ABSTRACT**

As of early 2020, humanity is facing an epidemic of severe acute respiratory syndrome caused by coronavirus a combination of SARS-CoV-2 and SARS-COV. SARS-CoV-2 causes coronavirus illness, abbreviated as COVID-19. With COVID-19, the degree of unhealthiness varies, starting from well to sharp rise and fatal. The World Health Organization estimates that serious unhealthiness may occur in as many as 13.8% of cases and 6.1% may be critical. This Viewpoint argues that human convalescent plasma is an associate in nursing care for treatment of COVID-19 illness. Convalescent sera could be used to treat patients with early symptoms and stop illness in those exposed. Hence, as we have a tendency to observe the unit of measurement within the worldwide pandemic, we have a tendency to tend to advocate that institutions deem the emergency use of convalescent sera and begin preparations presently. The novel coronavirus infection (COVID-19 or Coronavirus unwellness 2019) that emerged from Wuhan, Hubei province of China has spread to several countries worldwide. Efforts are made to develop vaccines against human coronavirus (CoV) infections like MERS and SARS within the past decades. However, to date, no authorised antiviral treatment or immunizing agent exists for MERS and SARS. Most of the efforts for developing CoV vaccines and medicines target the spike protein or S protein, the most important inducer of neutralizing antibodies. Though a couple of candidates have shown effectualness in invitro studies, not several have progressed to randomised animal or human trials, hence might have restricted use to counter COVID-19 infection. This text highlights the progress and advances in coming up with vaccines and medical speciality to counter COVID-19 whereas additionally those which specialize in such experiences and advances created with earlier SARS- and MERS-CoVs, which may modify efforts to halt this rising viral infection.

**Keywords:** Plasmapheresis, Morbilli, Grippe, Coronavirus, Monoclonal Antibody

\*Corresponding Author Email: [saurabhgpt30@gmail.com](mailto:saurabhgpt30@gmail.com)

Received 05 October 2020, Accepted 04 November 2020

Please cite this article as: Gupta SS *et al.*, COVID-19, an emerging coronavirus infection: Advances and prospects in designing convalescent sera, immunotherapeutics and therapeutics. British Journal of Medical and Health Research 2020.

## INTRODUCTION

As of early 2020, humanity is facing an epidemic in severe acute respiratory syndrome coronavirus (SARS-CoV-2). SARS-CoV-2 causing coronavirus sickness, abbreviated as COVID-19. Associate in Nursing, countable 100,000 individuals have already been infected with nearly 3300 deaths attributed to the sickness (termed COVID-19) <sup>1</sup>. The planning for effective treatment is afoot with multiple investigations currently across the World. Chinese authorities have reportable success treating infected patients with convalescent plasma from survivors of the unhealthiness, the planned profit being protective antibodies produced by the survivors <sup>2</sup>. Plasma transfusion and blood purification aren't novel therapies, that we tend to propose therapeutic plasma exchange as a possible treatment for unforeseen COVID-19. With COVID-19, the degree of unhealthiest varies, starting from well to unforeseen and fatal. The World Health Organization estimates that serious unhealthiness might occur in as many as 13.8% of cases and 6.1% may be critical <sup>3</sup>. Once unforeseen, patients might develop infection, acute respiratory distress syndrome (ARDS), and/or multiple organ failure that aren't distinctive to coronavirus, whereas treatment of the virus itself is definitely desired, treatment of the general response is perhaps attending to be the additional necessary facet of care and will be sharply wished. This host response to infection has been well delineated and involves an elaborate interaction of super molecule storm, inflammation, animal tissue pathology and pathologic action <sup>4-8</sup>. The pathway is common to multiple inciting events and has been the target of treatment for years, with therapeutic plasma exchange unambiguously providing profit on multiple levels by removing inflammatory cytokines, stabilizing animal tissue membranes and resetting the hypercoagulable state <sup>4, 8, 9</sup>. This Viewpoint argues that human convalescent plasma is associated in Nursing care for interference and treatment of COVID-19 sickness which may be quickly offered once there are enough numbers of individuals

### Historical Precedents

In the early twentieth century convalescent sera was accustomed stem outbreaks of organism diseases like communicable disease <sup>16</sup>, contagion <sup>17, 18</sup>, mumps <sup>19</sup>, and contagious disease <sup>20</sup>. A retrospective meta-analysis of eight studies on the use of convalescent sera involving 1703 patients throughout the 1918 H1N1 contagious disease virus pandemic urged that people who received liquid substance had lower mortality <sup>21</sup>. Although the power of convalescent sera varied with the virus and so the study, there was accord at the time that this intervention was useful, and it had been employed in varied outbreaks. it's noteworthy that historically, convalescent sera were developed and employed in many cases whereas not the means to live super molecule titers or information relating to organism serotypes, and in clinical studies that failed to meet stylish criteria for organization or dazzling. heaps of recently, convalescent liquid

substance was used throughout organism epidemics. at intervals the 2009–2010 H1N1 contagious disease virus pandemic, convalescent liquid substance super molecule preparations obtained by apheresis were accustomed treat individuals with severe H1N1 2009 infection requiring treatment <sup>22</sup>. Serum-treated individuals manifested reduced biological process organism burden, liquid substance super molecule responses, and mortality <sup>22</sup>. Convalescent liquid substance was in addition used among the 2013 West African viral haemorrhagic fever epidemic.

### **Plasma Merchandise by Donor Apheresis Description**

The donor apheresis understood the given plasma by volunteers to be employed in transfusion or conversion to some specific merchandise in plasma process center <sup>21</sup>.

### **Complications of Donor Plasma**

The donor plasma is far however the whole donor blood cell with the speed of adverse reactions in donors' blood elements <sup>22-23</sup>. AAFP: apheresis recent frozen plasma; zero.5% to 2.5%; Rare: < zero.5%; terribly rare: < zero.10%; Frequent: five-hitter to twenty Adverse reactions area unit a lot of in initial time donors and it's less vasovagal responses <sup>24</sup>. In contrary the whole blood donors, there area unit 2 reasons to cut back the blood volume (hypovolemia) that it's less reduction of blood volume than different donors in donors` apheresis. First, associate ejecting of the whole blood volume is sometimes however blood donors throughout donor apheresis and or the loss volume area unit getting to be remunerated if it required various and replacement fluids. Second, once apheresis has been done, at the same time donors have associate extended time constant that it had been compared with the whole blood donors and permits to refill the intervascular to the opening capillaries with blood <sup>24, 25-27</sup>. There area unit plasma intumescency and pain of needle among the injection house of the body that is the foremost common complication among the donor plasma however the incidence of intumescency wasn't over blood donors. There area unit seldom allergies once it had been ready to rub the iodine fluid to skin. it had been a vital adverse result associated with medicinal drug change state once used as medicinal drug in vitro system and it had been a region of the remaining blood elements back to the donor's blood. If donors have a low weight, perhaps they have several symptoms of change state <sup>28-30</sup>. generally there area unit rare gentle reactions to change state (anesthesia round the mouth, tremor or tingling sensation, tingling, or feeling cold or stuffy nose) and If the patients area unit baby-faced with these reactions it's not fearful however incontestable that doctors ought to management this method to scale back and forestall serious symptoms of change state toxicity. Generally reactions have acute forms because of change state toxicity (muscle cramps, whole body vibration, nausea, disgorgement and tetanus) that area unit rare in apheresis however probably area unit a big downside and disorder <sup>31-33</sup>.

### **Therapeutic Apheresis or Therapeutic Plasma Exchange (TPE)**

## DESCRIPTION

Therapeutic plasma exchange or TPE are typically attributed to plasma that exits from the body of patient then stipendiary by any quite replacement fluid volumes to support neuromeric scenario of patients <sup>34</sup>

### **What options ought to Morbific materials withdrawn by TPE should have?**

There are clinical reactions to the withdrawal plasma by TPE, if the microorganism has the subsequent properties <sup>35</sup>: one –

1. A withdrawal material should be sufficiently giant and as huge as macromolecules (molecular weight quite fifteen, 000), so it's not simply purified by a less expensive techniques like hemofiltration or irrecoverable high flux hem-dialysis.
2. Comparatively removed material includes a long half-life so in vitro removal of such substances into the body is passed abundant quicker than the clearing manner of the body known as metabolism. For instance, the immune gamma globulin with A some twenty one day's half-life albeit it is a treatment with immune-suppressors and stops manufacturing new antibodies when twenty one days, its decrease was at five hundredth.
3. A synthesis of the desired materials options an occasional speed. Intravascular concentration is commonly magnified and its deletion depends on the speed of their synthesis.
4. Microorganism is AN intravascular issue. the last word result of TPE depends on concentration of microorganism, and conjointly the concentration of that substance in any of the vessels and therefore the rate of exchange between these 2 components is that if every proportion of each within and outdoors of the vessel is larger than the opposite half and therefore the rate of exchange between the 2 components is low, the effectiveness of TPE would be high.
5. The removed materials should be very ototoxic and proof against typical medical aid so as that its fast elimination from the body fluid by TPE be potential because of the very fact that plasma exchange are going to be long and dear <sup>35</sup>.

At each stage of the TPE method, what proportion plasma ought to be removed? Plasma's volume that ought to be removed at every stage of TPE and its performance distances, the plasma issue depends on the microorganism <sup>36</sup>. Once the removed plasma (one volume plasma) has been occurred, AN equal volume of plasma clearance wasn't 100 percent and concerning thirty eighth of the material remains among the plasma thanks to the coinciding dilution and advanced plasma among the patient throughout the performance of TPE method by replacement fluids. when exchanging one.5 volumes of plasma, it remains twenty second and when replacement 2 volumes are V-J Day in thought-about substances .

If the high volume of plasma replaced, a smaller fraction of remained substances are typically removed till the speed of removing cut and it's reduced the removed volumes concerning one.5-2 equivalent of the plasma volume. It ought to be noted that the exchange of quite one plasma volume, caused to length the time interval of exchange and decreasing the patient endurance and conjointly increasing the price (replacing a plasma volume concerning one.5-2 hours long and by two to three equivalent of the degree exchange adds time of the process). in step with decreasing the microorganism removal potency in volumes larger than one.5 times of the plasma volume that calculable for every individual and adverse results of skyrocketing the time of activity TPE method caused to extend the degree of exchange, most therapeutic plasma exchange procedures aimed to get rid of concerning 1-1.5 plasma volumes in every turns <sup>37</sup>. How typically ought to the TPE procedure be performed? The variations in plasma levels exchange are depends on factors like the speed of patient illnesses, the speed of regeneration (re-synthesis) and distribution (the transfer of desired material to the intravascular) of additional tube-shaped structure substances <sup>38</sup>. for instance, the exit of immune gamma globulin should a daily TPE method (due to the high rate of synthesis and entry into the intravascular area outside the vessel ) and or among the patient WHO are awaiting a liver transplant, typically TPE is vital to sustain life each twelve hours and frequently , if a quantity of latest immune gamma globulin production is low (created throughout immunological disorder therapy), that the number of extra-vascular exchange is concerning 1-2% in hours against intravascular exchange needed five times TPE throughout seven to ten days to come ninetieth of initial body raise antibody <sup>39,40</sup>. How much plasma exchange is in an exceedingly TPE method? General recommendations of AABB for the TPE process indicated that in cases wherever there is its immune gamma globulin, the exchange of plasma volume calculable concerning 1-1.5 equivalent in everybody and once each 2-3 days with total exchanging in 3-5 days <sup>41,42</sup>. It ought to be, of course, noted that the frequency of plasma exchange might modification in step with the patient's clinical responses and laboratory testing results.

#### **What form of medicine and the way abundant is needed?**

Citrate, heparin, or each combos are usually used throughout apheresis to prevent the blood circulation outside the body. Patient ought to be fastidiously evaluated in terms of the ability against turn or Lipo-Hepin, to figure out the best medicine materials. Alternative concerns embrace the thanks to assess intravascular volume of patient, the kind and volume of replacement fluid, endovenous access and blood flow inside the tube. turn has been accessed in four shapes as follows <sup>43</sup>: ACD-A, ACD-B, metal turn and concentration of tri-sodium turn ACD-A has been prescribed inside the number of 9:1 to 14:1 that together with third-dimensional metal turn and additionally utilized within the determined rate of medical aid (WB/ACD) in blood. In distinction to ACD-A,

ACD-B is together with two metal turn that generally used at the speed of 6:1 to 9:1 from WB/ACD to reduce the turn toxicity risk. in contrast to Lipo-Hepin, turn has not any fast metabolization. it is the precise half-life of roughly ninety minutes and so ends up in have general medicine effects in patients <sup>44</sup>. once these specific characteristics are replaced with non-plasma fluids throughout apheresis (e.g. albumen five-hitter or HES) it's tough to induce obviate the curdling factors in plasma and their replacement. Lipo-Hepin are usually used alone or along with ACD-A and or ACD-B. once they use the mixture of Lipo-Hepin and turn to form effective medicine effects, Lipo-Hepin is needed less and fewer ACD volumes. Therefore, this combine reduced the incidence of general toxicity turn medical aid because of minimizing the Lipo-Hepin consumes alone and additionally reduces the complete volumes of the injected fluid throughout TPE method <sup>45</sup>.

### **In vitro, what quite tests want throughout the TPE process?**

Studies are supported the last word goal of medical aid and pursuing of the reduction issue. apheresis are usually evaluated associate degreed studied an early CBC thought, activity humour macromolecule, electrolytes and coagulator factors <sup>46</sup>. Additional careful laboratory associate degree lysis is needed once desired an large variety of low- frequency plasma exchange. continuously we must always} always offer many hour probabilities to body to follow the specified laboratory TPE tests till to shift extra- and intra-vascular fluids to reach equilibrium and haemorrhage possesses to be taken particularly in organic chemistry.

### **CONCLUSION**

Plasmapheresis, that is outlined as a result of the removal of plasma, are typically either “adjusted plasma” or “exchange of plasma”. pheresis is presently used as a therapeutic modality throughout an enormous choice of conditions. Generally, pheresis is utilized once a substance at intervals the plasma, like human gamma globulin, is acutely deadly and will be with efficiency removed. Myriad conditions fall under this class, as well as medicine, medicine, metabolic, medicine, rheumatologic, and excretory organ diseases, additionally as intoxications, which can be treated with pheresis. Researchers are finding out effective and appropriate vaccinum candidates and medicine for dominant the deadly COVID-19. There don't seem to be any effective vaccines or specific antiviral medicine for COVID-19. Hence, we've to swear solely on imposing strict preventive and management measures that minimize the danger of potential sickness transmission. Results obtained from the recently conducted in vitro study against COVID-19 are promising since the medicine Remdesivir and antimalarial were found to be extremely effective in dominant the infection. Direct clinical trials are typically conducted among the patients infected with COVID-19 since these medicine have

gotten used for treating different diseases and have well-established safety profiles, creating the any analysis of these medicine a lot of easier.

## REFERENCES

1. Hawkins D, Knowles H, Brice-Saddler M et al. US coronavirus death toll reaches 17; at least half of US states confirm cases. Washington Post 2020. <https://www.washingtonpost.com/world/2020/03/06/coronavirus-liveupdates>. Accessed 7 Mar 2020.
2. Bloomberg. China finds promising coronavirus treatment in blood plasma. Fortune. February 14, 2020. <https://fortune.com/2020/02/14/china-coronavirus-treatment-blood-plasma-recovered-patients/>. Accessed 7 Mar 2020.
3. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16–24 February 2020. <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>.
4. Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. *Thromb J.* 2019;17:10. <https://doi.org/10.1186/s12959-019-0198-4>.
5. Gyawali B, Ramakrishna K, Dharmoon AS. Sepsis: the evolution in definition, pathophysiology, and management. *SAGE Open Med.* 2019;7:2050312119835043. Published 2019 Mar 21. <https://doi.org/10.1177/2050312119835043>.
6. Hou PC, Filbin MR, Wang H, et al. Endothelial permeability and hemostasis in septic shock: results from the ProCESS trial. *Chest.* 2017;152(1):22–31.
7. Johansson P, Stensballe J, Ostrowski SR. Shock induced endotheliopathy (SHINE) in acute critical illness – a unifying pathophysiologic mechanism. *Crit Care.* 2017;21:25 <https://doi.org/10.1186/s13054-017-1605-5>.
8. Nguyen T, Carcillo J. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure - a newly appreciated syndrome in the critically ill. *Crit Care.* 2006;10(6):235. <https://doi.org/10.1186/cc5064>.
9. Knaup H, Stahl K, Schmidt BMW, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. *Crit Care.* 2018;22:285 <https://doi.org/10.1186/s13054-018-2220-9>.
10. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis.* 1995;21(1):150–161.

11. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. *Nat Rev Microbiol.* 2004;2(9):695–703.
12. Zhang JS, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. *J Med Virol.* 2005;77(2):147–150.
13. Beigel JH, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: a phase 1 randomized, double-blind, single-dose-escalation study. *Lancet Infect Dis.* 2018;18(4):410–418.
14. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. *J Infect Dis.* 1995;171(6):1387–1398.
15. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. *Trends Immunol.* 2003;24(9):474–478.
16. Park WH. Therapeutic use of antipoliomyelitis serum in paralytic cases of poliomyelitis. *JAMA.* 1932;99:1050–1053.
17. Park WH, Freeman RG. The prophylactic use of measles convalescent serum. *JAMA.* 1926;87(8):556–558.
18. Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. *Am J Public Health Nations Health.* 1935;25(5):595–598.
19. Rambar AC. Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis. *Am J Dis Child.* 1946;71:1–13.
20. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. *Crit Care Med.* 2010;38(4 suppl):e66–e73.
21. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med.* 2006;145(8):599–609.
22. Hung IF, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis.* 2011;52(4):447–456.
23. Gajic O, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med.* 2007;176(9):886–891.
24. Wan Y, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. *J Virol.* 2020;94(5):e02015-19.

25. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. *Antiviral Res.* 2017;137:82–92. doi:10.1016/j. antiviral.2016.11.006.
26. Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerging Microbes Infect.* 2020;9 (1):275–77. doi:10.1080/22221751.2020.1723441.
27. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel corona virus responsible for a pneumonia outbreak originating in Wuhan, China. *Microbes Infect.* 2020. S12864579(20)30025–3. doi:10.1016/j.micinf.2020.01.003.
28. Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. *Chembiochem.* 2020. doi:10.1002/cbic.202000047.
29. Veljkovic V, Vergara-Alert J, Segalés J, Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. *F1000Research.* 2020;9(52):52. doi:10.12688/f1000research.22149.1.
30. Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. *J Med Virol.* 2020. doi:10.1002/jmv.25698.
31. Shi J, Zhang J, Li S, Sun J, Teng Y, Wu M, Li J, Li Y, Hu N, Wang H, et al. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases. *PLoS One.* 2015;10(12):e0144475. doi:10.1371/journal.pone.0144475.
32. Xie Q, He X, Yang F, Liu X, Li Y, Liu Y, Yang Z, Yu J, Zhang B, Zhao W. Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome-coronavirus. *IEEE/ACM Trans Comput Biol Bioinform.* 2018;15(4):1344–50. doi:10.1109/TCBB.2017.2702588.
33. Bijlenga G. Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands. *J Infect.* 2005;51(3):263–65. doi:10.1016/j.jinf.2005.04.010.
34. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. *J Med Virol.* 2020. doi:10.1002/jmv.25707.

35. NIAID. Developing therapeutics and vaccines for coronaviruses; 2020. [accessed 2020 Feb 15]. <https://www.niaid.nih.gov/diseasesconditions/coronaviruses-therapeutics-vaccines>
36. CEPI. CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019; 2020. [accessed 2020 Feb 15]. [https://cepi.net/news\\_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/](https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/)
37. Moderna. Moderna announces funding award from CEPI to accelerate development of messenger RNA (mRNA) vaccine against novel coronavirus; 2020. [accessed 2020 Feb 15]. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development>
38. Goo J, Jeong Y, Park Y-S, Yang E, Jung D-I, Rho S, Park U, Sung H, Park P-G, Choi JA. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. *Virus Res.* 2020;278:197863. doi:10.1016/j.virusres.2020.197863.
39. Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, Shi ZL. Cross neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. *Sci China Life Sci.* 2017;60 (12):1399–402. doi:10.1007/s11427-017-9189-3.
40. Cohen J. New coronavirus threat galvanizes scientists. *Science.* 2020;367(6477):492–93. doi:10.1126/science.367.6477.492.
41. Seesuy W, Jittavisutthikul S, Sae-Lim N, Sookrung N, Sakolvaree Y, Chaicumpa W. Human transbodies that interfere with the functions of Ebolavirus VP35 protein in genome replication and transcription and innate immune antagonism. *Emerging Microbes Infect.* 2018;7 (1):41. doi:10.1038/s41426-018-0031-3.
42. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. *Curr Opin Virol.* 2015;13:123–29. doi:10.1016/j.coviro.2015.06.009.
43. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. *Front Microbiol.* 2019;10:1781. doi:10.3389/fmicb.2019.01781.
44. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Peiris JS, Lim W, Osterhaus AD. *Virology: SARS virus infection of cats and ferrets.* *Nature.* 2003;425(6961):915. doi:10.1038/425915a.
45. Roberts A, Wood J, Subbarao K, Ferguson M, Wood D, Cherian T. Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical

meeting 25-26 August 2005, London, UK. *Vaccine*. 2006;24(49–50):7056–65. doi:10.1016/j.vaccine.2006.07.009.

46. Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, et al. A live 6 K. DHAMA ET AL. attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. *J Virol*. 2008;82(15):7721–24. doi:10.1128/JVI.00304-08.

**BJMHR is**

- **Peer reviewed**
- **Monthly**
- **Rapid publication**
- **Submit your next manuscript at**

**editor@bjmhr.com**

